major depressive disorder newsletter

Major Depressive Disorder (MDD), also known as clinical depression, is a severe, debilitating and frequent psychiatric disorder. The treatment landscape generally revolves around different types of anti-depressants. However, over 20 drugs are in the different phases of development. Major Depressive Disorder, often simply called depression, is a serious and common mental health condition that profoundly affects how individuals feel, think, and handle daily activities. It is one of the most prevalent psychiatric disorders globally and can occur at any age, although it most commonly emerges in adulthood.

Read more about the standard of care available, therapies in the pipeline, and clinical trials ongoing in the Major Depressive Disorder market. The newsletter also offers a picture of the MDD market outlook, unmet needs, ongoing R&D and happenings on the research front. Major Depressive Disorder is characterized by persistent sadness or a lack of interest in external stimuli, significantly impairing a person's daily functioning. Unlike normal fluctuations in mood or temporary feelings of sadness, MDD is long-lasting and can interfere with a person’s ability to work, sleep, eat, and enjoy life.

To be diagnosed with MDD, symptoms must be present for at least two weeks and represent a change from previous functioning. It is not the same as grief or bereavement, though the two can share features.

Subscribe to our newsletter series for more insights into pharma market research, unmet needs and ongoing clinical trials.

Drop us an email for more consulting and business solutions.

Stay in the loop!